4-(Methylthio) Acidum phenylaceticum CAS 16188-55-9 Puritas >98.0% (GC) Etoricoxib Intermedia
Shanghai Ruifu Chemical Co., Ltd. est primarium fabrica et supplementum 4-(Methylthionis) phenylaceticae acidum (CAS: 16188-55-9) cum qualitate magna.CoA praebere possumus, totius orbis partus, parvas et parvas quantitates in promptu habentes.Si interesse in hoc facto, singula informationes mittas mitte nobis numerum CAS, nomen productum, quantitatem nobis.Please contact: alvin@ruifuchem.com
| Nomen chemicum | 4-(Methylthio) phenylaceticum acidum |
| Synonyma | 4-Methylthiophenylacetic Acidum;2-(4-(Methylthio)phenyl)acetic Acidum;2-[4-(Methylsulfanyl)phenyl]acetic Acidum;4-(Methylthio) acidum benzeneaceticum |
| CAS Number | 16188-55-9 |
| CATTUS Number | RF-PI1183 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C9H10O2S |
| M. Pondus | 182.24 |
| Liquescens punctum | 96.0~99.0℃ (lit.) |
| Ferveret | 337.4±25.0℃ (lit.) |
| Density | 1.23±0.10 g/cm3 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba ad lux Yellow pulveris |
| Puritas / Analysis Methodus | >98.0% (GC) |
| Puritas / Analysis Methodus | > 98.0% (Titration Neutralization) |
| Liquescens punctum | 96.0~99.0℃ |
| Damnum in Siccatio | <1.00% |
| Residere in Ignition | <0.50% |
| Totalis immunditias | <2.00% |
| Test Standard | Enterprise Standard |
| Consuetudinem | Medium Etoricoxib (CAS: 202409-33-4) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
4-(Methylthio) Acid phenylaceticum (CAS: 16188-55-9) est clavis media ad praeparationem Etoricoxib (CAS: 202409-33-4).Etoricoxib est genus cyclooxygenasi valde selectivi-2 (COX-2) inhibitores a comitatu Merck elaboratum cum nomine chemico 5-chloro-6'-methyl-3-4-(methanesulfonamide) phenyl]-2, 3'- bipyridine.Etoricoxib unicam habet structuram chemicam quae est coetus methylsulfonyl.Huius coetus introductio non solum selectivity COX-2 pharmacorum auget, sed etiam medicamenta sulfa non gignit et motus allergicos cross.Etoricoxib late in curatione OSTEOARTHRITIS (OA), arthritis rheumatoideis, spondylitis ankylosing, longis retro dolor, podagris acutis, arthritis primariis dysmenorrhea et postoperative, aliisque morbis.
